Charles River Laboratories International Inc. has announced a strategic alliance with the Parker Institute for Cancer Immunotherapy (PICI) to enhance its oncology manufacturing portfolio. This collaboration aims to accelerate the development of cell and gene therapies for cancer treatment. Through this partnership, PICI network members will gain access to Charles River's comprehensive range of preclinical drug discovery and development services, from early discovery to manufacturing. The collaboration is designed to maximize knowledge transfer, reduce bottlenecks, and expedite drug development, aligning with PICI's mission to bring treatments to patients faster and Charles River's goal of creating healthier lives.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250911606575) on September 11, 2025, and is solely responsible for the information contained therein.